Janet Griffiths, PhD

Experience

• 

  MIT and Merck Manufacturing Division (MMD)

  Sept 1994 - Jul 1997

  Assistant Professor & Program Director

  Assistant Professor, Chemical Engineering and Program Director of MIT School of Chemical Engineering Practice (based at Merck Manufacturing Division, West Point, PA).

• 

  Genzyme Corporation

  Jul 1997 - Jan 2002

  Director, Therapeutics Manufacturing & Development

  Director of Manufacturing Technical Support for Genzyme's late stage and commercial programs. Managed team of 19 scientist and engineers. Led capacity improvement and scale-up progams for Cerezyme and Fabrazyme. Responsible for due diligence and integration planning representing all of Operations during period of very active growth via business development.

• 

  Biogen Idec

  Feb 2002 - Jun 2011

  Program Executive for all Biogen Research and Development (R&D) Immunology Programs. Chief of Staff for Sr. VP of Immunology R&D. Expansion of early stage clinical development programs into Neurology and Oncology therapeutic areas. Alliance Manager for R&D relationship with UCB. Assessment of technical and organizational aspects of establishing a biosimilars pipeline. Built team of 16 scientists and engineers during phase of rapid expansion at Biogen Idec. Responsible for bulk and drug product manufacturing for all of Biogen's clinical programs in addition to commercial products Avonex, Amevive and Phase 3 supply for Tysabri. Initiated and advanced innovative Process Analytic Technologies (PAT) including novel tools for process modeling. CMC Lead for multiple early stage and one Phase 3 in-licensed program.

  • Program Executive

    Oct 2004 - Jun 2011

  • Associate Director Manufacturing Sciences

    Feb 2002 - Oct 2004
• 

  Human Genome Sciences/GSK

  Jun 2011 - Dec 2012

  Senior Director, Global Program Management

  R&D strategy and program leadership for active immunology pipeline. Medical Affairs support for Benlysta (belimumab) in systemic lupus erythematosus (SLE). Strategic asset management. Member of leadership team for acquisition of HGS by GSK effective July 2012.

• 

  AstraZeneca

  Dec 2012 - Aug 2023

  As Program Leader, led TEZSPIRE (tezepelumab; anti-TSLP) from early clinical phase development through Phase 3 investment as part of a collaboration with Amgen. During Phase 3, I transition to Head of Translational Medicine for the portfolio of early and late AstraZeneca/Medimmune biologics including TEZSPIRE. Disease areas of study included severe asthma, COPD, chronic urticaria, atopic dermatitis, eosinophilic esophagitis, and chronic sinusitis with nasal polyps (CRSwNP). Program Leader for multiple early stage assets including development in severe asthma, COPD, atopic dermatitis, eosinophilic esophagitis and systemic lupus erythematosis (SLE).

  • Executive Director and Chief Scientist

    Jul 2021 - Aug 2023

  • Head of Translational Medicine Development: Respiratory, Inflam and Autoimmunity

    Feb 2018 - Jul 2021

  • Global Program and Alliance Leader (Medimmune)

    Dec 2012 - Jan 2018